Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT05678673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05678673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 1, 2023
Completion date
June 30, 2028
Enrollment
317 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

non-clear cell renal cell carcinoma